At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas Treatment Study
This randomized phase II trial studies how well temozolomide and capecitabine work compared to standard treatment with cisplatin or carboplatin and etoposide in treating patients with neuroendocrine carcinoma of the gastrointestinal tract or pancreas that has spread to other parts of the body (metastatic) or cannot be removed by surgery. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Certain types of neuroendocrine carcinomas may respond better to treatments other than the current standard treatment of cisplatin and etoposide.
In order to participate you must meet the following criteria:
- Have locally advanced and unresectable or metastatic gastroenteropancreatic neuroendocrine carcinoma that is either known or suspected to be of gastrointestinal (GI) origin.
- Have measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria.
You will be excluded from the study if any of the following criteria apply to you:
- Have primary tumors arising from the lung, gynecologic organs or prostate.
- Have had any prior systemic treatment for this malignancy.
This is a partial list of inclusion and exclusion criteria.